Infectious Respiratory Disease Diagnostics Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

The infectious respiratory disease diagnostics market includes a broad array of testing technologies, such as molecular assays, immunoassays, and microbiology culture methods, used to identify pathogens responsible for acute and chronic respiratory infections. Beyond the overall infectious disease diagnostics segment valued at $26.58 billion in 2025, the respiratory-specific component represents a substantial and increasingly critical share, driven by recurring seasonal outbreaks and ongoing pandemic threats. The market spans hospital and clinical laboratories, commercial reference laboratories, and an expanding network of decentralized point-of-care settings where results can be delivered in minutes rather than days.

• •Molecular diagnostics, including PCR and next-generation sequencing platforms, now represent a major and fast-growing share of total market revenue
• •Point-of-care testing is gaining market share as healthcare systems prioritize rapid diagnostics that support immediate clinical decisions
• •The COVID-19 pandemic fundamentally expanded testing infrastructure, with many investments and capabilities now repurposed for broader respiratory surveillance

Persistent and evolving respiratory threats, including seasonal influenza, respiratory syncytial virus, tuberculosis, and novel coronaviruses, sustain robust and recurring demand for diagnostic services worldwide. Aging populations in developed economies increase the pool of individuals at higher risk for severe respiratory infections, while urbanization and dense population centers in emerging markets amplify transmission dynamics. Additionally, the COVID-19 experience elevated government awareness of the costs associated with delayed outbreak detection, driving investments in national diagnostic preparedness programs across multiple continents.

• •Growing incidence of co-infections and dual respiratory conditions is increasing demand for multiplex testing panels capable of simultaneously detecting multiple pathogens
• •Rising awareness of antimicrobial resistance is fueling demand for rapid diagnostics that can guide appropriate targeted treatment decisions
• •Healthcare policy shifts toward value-based care and early disease detection are encouraging wider adoption of diagnostics over empirical treatment approaches

The market is segmented by technology into molecular diagnostics, immunoassays, microbiology, and emerging platforms, with molecular testing commanding premium pricing and growing adoption due to its superior sensitivity and speed. End-user channels include hospital laboratories, commercial diagnostic laboratories, and point-of-care facilities, each contributing distinctively to overall revenue. Geographically, North America dominates with an infectious disease diagnostics market valued at approximately $8.48 billion in 2025, while Europe and Asia-Pacific represent the next largest regions, with Asia-Pacific expected to see the most aggressive growth trajectory through 2030.

• •North America is projected to reach roughly $14.94 billion by 2033, growing at an annual rate of approximately 7.34 percent within that regional scope
• •Asia-Pacific, particularly China, India, and Southeast Asian nations, is anticipated to post the strongest CAGR as healthcare spending rises and testing access broadens
• •Emerging markets in Latin America, the Middle East, and Africa are beginning to attract greater investment as international health organizations prioritize diagnostic capacity building

What are the recent trends and outlook?

Looking forward through 2030, the market is expected to benefit from continued technological convergence, with artificial intelligence, microfluidics, and novel genomic technologies improving the accuracy, speed, and cost-effectiveness of respiratory diagnostics. Multiplex respiratory panels capable of detecting ten or more pathogens in a single sample are increasingly replacing individual pathogen tests, offering both clinical and economic advantages. Decentralized testing models, including at-home collection, mobile testing units, and near-patient laboratory solutions, are expected to expand the addressable market by reaching populations with limited access to centralized facilities.

• •CRISPR-based diagnostic technologies are emerging as a potential disruptive force, offering high sensitivity with the simplicity and rapid turnaround time needed at the point of care
• •The molecular diagnostics sub-segment is projected to expand significantly from roughly $15.85 billion in 2024 toward $22.45 billion by 2030, reflecting its outsized role in overall market growth
• •Sustained industry and government investment in pandemic preparedness, combined with the institutionalization of surveillance testing programs, is expected to support consistent long-term demand growth